Figure 2

Impact of pre-transplant transfusion on allosensitization. (A) Proportion of patients sensitized stratified by pre-transplant transfusion status. (B) Risk of allosensitization by number of pre-transplant transfusions. *Significant difference as reported in the original publication; ^†represents sensitization measurement not explicit, but identified according to the text; ^‡data reported for 0–5 transfusion vs. > 5 transfusions; values have been rounded to the nearest integer. NOTE: Additional calculation has been performed to allow for comparison between the populations of interest. Therefore, the numbers presented differ from those presented in the primary source publications with the exception of Lim 1992, Direskeneli 1992, and Lietz 2003. CDC: complement-dependent cytotoxicity; ELISA: enzyme-linked immunosorbant assay; FXCM: flow cytometry cross-match; HLA: human leukocyte antigen; Mixed: probable CDC + flow cytometry; MPC: mean peak channel; NR: not reported; PRA: panel reactive antibodies; +ve: positive.